MXCT
MaxCyte Inc

438
Mkt Cap
$181.35M
Volume
84,650.00
52W High
$5.20
52W Low
$1.26
PE Ratio
-3.96
MXCT Fundamentals
Price
$1.69
Prev Close
$1.70
Open
$1.69
50D MA
$1.61
Beta
1.44
Avg. Volume
582,071.74
EPS (Annual)
-$0.3916
P/B
1.01
Rev/Employee
$338,833.33
Loading...
Loading...
News
all
press releases
MaxCyte (NASDAQ:MXCT) Upgraded to Hold at Wall Street Zen
Wall Street Zen upgraded shares of MaxCyte from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
FY2025 EPS Estimates for MaxCyte Boosted by William Blair
MaxCyte, Inc. (NASDAQ:MXCT - Free Report) - Stock analysts at William Blair upped their FY2025 earnings per share estimates for MaxCyte in a report released on Thursday, November 13th. William Blair...
MarketBeat·9d ago
News Placeholder
MaxCyte (NASDAQ:MXCT) Announces Quarterly Earnings Results
MaxCyte (NASDAQ:MXCT - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus...
MarketBeat·12d ago
News Placeholder
Insights into MaxCyte's Upcoming Earnings
read more...
Benzinga·15d ago
News Placeholder
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates
Avidity Biosciences (RNA) delivered earnings and revenue surprises of -20.95% and +399.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates
ANI (ANIP) delivered earnings and revenue surprises of +17.24% and +7.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
chainwire·7mo ago
News Placeholder
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)
Glancy Prongay & Murray LLP (GPM) announces its investigation of MaxCyte, Inc. (NASDAQ: MXCT) concerning the Company and its directors and officers possible violations of state laws. If you own...
Business Wire·10mo ago
News Placeholder
MaxCyte Director Executes Stock Options and Sells
MaxCyte (MXCT) has released an update. MaxCyte Inc., a leader in cell-engineering, has reported that their Non-Executive Director, John Johnston, h...
TipRanks Financial Blog·1y ago

Latest MXCT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.